AARD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026

Faruqi & Faruqi is investigating potential securities claims against Aardvark Therapeutics and says a federal securities class action has been filed against the company. Investors who purchased Aardvark securities in its February 13, 2025 IPO or during the February 13, 2025–May 14, 2026 class period have until October 13, 2026 to seek lead-plaintiff status.

Analysis

This is a procedural legal-overhang signal, not evidence that the allegations are valid or that AARD’s operating outlook has changed. The lead-plaintiff deadline may briefly raise attention and volatility, but the notice supplies no alleged misstatement, loss-causation theory, financial exposure, or new company disclosure from which to estimate fundamental impact. Avoid treating the law firm’s solicitation as independent confirmation of wrongdoing.

Near term, the key information catalyst is whether the complaint and subsequent court filings identify specific IPO or class-period disclosures that conflict with verifiable operating results. If so, potential second-order effects include management distraction, a litigation-related discount on future capital raising, and scrutiny of disclosure controls; these remain conditional, not established costs. Any settlement or defense burden would depend on facts not provided, including claims, insurance, and procedural outcomes.

AARD’s biotech and IPO profile can amplify headline-driven moves, but there is insufficient evidence here to infer product, cash-runway, or financing risk. The contrarian read is that investors may overreact to a routine plaintiff-recruitment notice; conversely, if the underlying complaint alleges a material, previously undisclosed business issue, this notice could understate the eventual disclosure overhang. No directional trade is justified on this item alone.

Key Decisions for Investors

• Do not initiate a position based solely on this notice. Check AARD’s price and volume response against the broader biotech sector; a sharp idiosyncratic selloff without new company facts may be a fade candidate, but only after reviewing the complaint.
• By the October 13 lead-plaintiff deadline, review the filed complaint and any company response for the specific alleged statements, disclosure dates, and claimed corrective event. Escalate only if these connect to operating or financial facts not already reflected in public disclosures.
• Monitor subsequent court rulings and company filings over the next 1–3 months; reassess if they reveal a material disclosure-control issue, guidance change, or financing impact. A dismissal or allegations unsupported by new facts would weaken the legal-overhang thesis.
• Before considering a hedge or pair trade, verify AARD’s liquidity, borrow availability, short interest, cash runway, and the alleged loss period. These data are absent, so event-driven sizing and downside exposure cannot be responsibly framed.